BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/19/2025 8:32:41 AM | Browse: 65 | Download: 360
 |
Received |
|
2025-07-03 13:03 |
|
Peer-Review Started |
|
2025-07-03 13:04 |
|
First Decision by Editorial Office Director |
|
2025-07-11 09:17 |
|
Return for Revision |
|
2025-07-11 09:17 |
|
Revised |
|
2025-07-23 15:49 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2025-10-27 02:41 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2025-10-27 08:42 |
|
Articles in Press |
|
2025-10-27 08:42 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2025-12-08 02:36 |
|
Publish the Manuscript Online |
|
2025-12-19 08:32 |
| ISSN |
2220-315x (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Cardiac & Cardiovascular Systems |
| Manuscript Type |
Randomized Controlled Trial |
| Article Title |
Sacubitril/valsartan as add-on to standard therapy in patients with heart failure: A randomized controlled trial
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Reevanshi Dhawan, Rakesh Mittal, Ashwani Kumar, Kuldip S Laller, Paramjeet S Gill, Adarsh Rag and Niti Mittal |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Niti Mittal, Associate Professor, DM, Department of Pharmacology, PGIMS, Medical Road, Null, Rohtak 124001, Haryana, India. drnitimittal@uhsr.ac.in |
| Key Words |
Sacubitril/valsartan; Neprilysin inhibitor; N-terminal pro-B-type natriuretic peptide; High-sensitivity C-reactive protein; World Health Organisation Quality of Life Questionnaire; Heart failure |
| Core Tip |
This randomized clinical trial evaluated the efficacy and safety of sacubitril/valsartan, a first-in-class angiotensin receptor neprilysin inhibitor, as add-on to standard therapy compared to standard therapy alone in patients with New York Heart Association functional class II-III heart failure (HF). A total of 80 patients were enrolled out of which 25 patients in each group were available for per-protocol analysis. Baseline demographic, clinical and biochemical characteristics in both the groups were comparable. Sacubitril/valsartan demonstrated significant improvements in HF biomarkers, inflammation, and quality of life after 12 weeks without compromising safety supporting its role as an effective addition to standard HF therapy. |
| Publish Date |
2025-12-19 08:32 |
| Citation |
Dhawan R, Mittal R, Kumar A, Laller KS, Gill PS, Rag A, Mittal N. Sacubitril/valsartan as add-on to standard therapy in patients with heart failure: A randomized controlled trial. World J Exp Med 2025; 15(4): 111542 |
| URL |
https://www.wjgnet.com/2220-315x/full/v15/i4/111542.htm |
| DOI |
https://dx.doi.org/10.5493/wjem.v15.i4.111542 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
